- Liquid Biopsy
- Our technology enables the detection of the smallest amounts of DNA using probes, even in early cancers with low diagnostic rates and high sensitivity/specificity in array evaluations.
In particular, the methylation percentage can be quantified to provide a technology that enables cancer diagnosis.
- DNA Sequencing
- Base sequences in DNA generate changes of charge in several na units. These changes are detected and linked to reference sequences with AI-based sequencing platforms.
- Diagnostic Platform
- The diagnostic platform can be used for cancer diagnosis, biopharmaceutical performance testing and biopharmaceutical development, providing an optimal environment for multiple diagnoses or analysis of long sequences of 10K bases or more.
- Smart Healthcare System
- By applying DNA sequencing, we can develop specific biomarkers that can detect early cancers or adult diseases, and manage them from disease to prognosis through biosensor and AI algorithm diagnoses.